Therefore, in the present study, we hypothesized that Curcumin might enhance the anti-tumor effects of Lenvatinib as a tyrosine kinase inhibitor and that the anti-EGFR potential of Curcumin could help overcome Lenvatinib resistance in HCC. This evidence concerns the gene EGFR and neoplasm.